Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Dato-DXd vs. SG in TNBC: compare TROP2 ADC mechanisms, linker-payload design, clinical signals, and IP landscape for datopotamab deruxtecan and sacituzumab govitecan.
Article | Rapport How does laser-based metal deposition compare to traditional welding for turbine blade tip restoration in MRO? Explore the key process differences, trade-offs, and patent trends.
Article | Rapport NLRP3 inhibitor VTX3232 is advancing toward Phase III in Parkinson's disease and cardiometabolic conditions — and Sanofi holds a right of first negotiation. Here's what the patent data reveals.
Article | Rapport How engineers use multi-physics co-simulation to design next-generation power electronic converters — thermal, EM, mechanical and circuit domain coupling explained.
Article | Rapport Fenebrutinib's Phase III trials in progressive MS target smoldering lesions via CNS-penetrant BTK inhibition. How does Roche's bet compare to tolebrutinib?
Article | Rapport How AI-powered generative design transforms the engineering workflow for lightweight satellite structural components — topology optimization, multi-objective automation, and manufacturing integration.
Article | Rapport TERN-701, Terns Pharmaceuticals' STAMP inhibitor targeting BCR-ABL's myristoyl pocket, prompted Merck's $6.7B acquisition. Explore the CML pipeline race.
Article | Rapport How engineers validate electromagnetic compatibility of active implantable devices under ISO 14117 — testing frameworks, immunity protocols, and regulatory requirements explained.
Article | Rapport Scholar Rock's apitegromab targets latent myostatin in SMA patients on risdiplam or nusinersen. Explore the patent landscape and muscle-targeted therapy rationale.
Article | Rapport How does robot-assisted minimally invasive surgery differ from conventional laparoscopy? Explore the key engineering design constraints shaping next-gen surgical systems.
Article | Rapport How engineers design explosion-proof enclosures for electronic systems in hazardous environments: ATEX, IECEx, flameproof methods, and certification strategies.
Article | Rapport Iberdomide's EXCALIBER-RRMM Phase III trial positions CELMoD agents as the next-generation successor to lenalidomide in relapsed/refractory multiple myeloma.
Article | Rapport How AI-assisted code generation is reshaping firmware development workflows for embedded systems engineers — productivity, IP, and best practices.
Article | Rapport MET/VEGFR inhibitor zanzalintinib combined with atezolizumab targets metastatic colorectal cancer via dual pathway blockade. Explore the molecular rationale and IP landscape.
Article | Rapport Lanifibranor's NATiV3 Phase III readout is the most anticipated MASH event of 2026. Explore the pan-PPAR mechanism, histological endpoints, and competitive pipeline.